ArticleFrontiers in immunology2026
Dynamic survival prediction using longitudinal AGR in unresectable locally advanced esophageal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitor (ICI)-based induction therapy followed by definitive radiotherapy has emerged as a promising treatment strategy for patients with unresectable locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, many patients still experience disease progression and poor clinical outcomes. Although longitudinal circulating biomarkers may provide valuable prognostic information, their dynamic predictive value in this treatment setting remains largely unexplored. Materials and methods: We retrospectively enrolled patients with unresectable LA-ESCC from a single medical center who received PD-1inhibitor-based induction therapy followed by definitive radiotherapy. In addition to baseline clinical and histopathological characteristics, 110 circulating biomarkers were serially collected throughout treatment to characterize longitudinal changes. A Bayesian joint model integrating baseline predictors with longitudinal biomarker trajectories was developed for dynamic survival prediction. Model discrimination and calibration were evaluated using time-dependent area under the receiver operating characteristic curve (AUCs) and Brier scores, respectively. Results: A total of 376 patients were included, comprising a training cohort (n = 221) and an independent temporal test cohort (n = 155), yielding 328,104 longitudinal biomarker measurements. Following multistage variable selection procedure, latent class growth analysis identified distinct longitudinal trajectories of the albumin-to-globulin ratio (AGR) that are significantly associated with survival outcomes. Dynamic AGR value and trajectory emerged as the most informative longitudinal predictors among all candidate biomarkers. In the training cohort, the 12-, 24-, and 36-month AUCs were 0.85 (95% CI, 0.82-0.89), 0.92 (95% CI, 0.90-0.94), and 0.87 (95% CI, 0.84-0.91), respectively. In the test cohort, the corresponding 12- and 24-month AUCs were 0.80 (95% CI, 0.75-0.85) and 0.82 (95% CI, 0.78-0.86), respectively. Conclusion: By integrating longitudinal AGR trajectories with baseline clinical information, the Bayesian joint model enables individualized, real-time prognostic updating and may facilitate dynamic risk stratification and risk-adapted management for patients with unresectable LA-ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.